COMP <GO>
TMCI vs MRK // GROSS PROFIT MARGIN
Treace Medical Concepts Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: TMCI 3
— MRK 8
▲ GROSS PROFIT MARGIN LEADER: TMCI
LAST: $5.06 (+4.76%) • MKT CAP: $329.1M
gross-margins
79.80%
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TMCI VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TMCI | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 79.80% | 74.80% | +5.00 | TMCI | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.40% | 20.70% | -53.10 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.96% | 3.42% | -12.38 | MRK | /fcf-yield <GO> |
| Operating Margin | -25.50% | 34.30% | -59.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | -27.70% | 28.10% | -55.80 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 1.60% | 1.30% | +0.30 | TMCI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.90 | 5.19 | -4.29 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.7 | 51.7 | +11.00 | TMCI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $329.1M | $361.02B | -$360.69B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TMCI REV | MRK REV | TMCI GROSS % | MRK GROSS % | TMCI FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $212.7M | $65.01B | 79.8% | 74.8% | -$29.5M | $12.36B |
| FY 2024 | $209.4M | $64.17B | 80.4% | 76.3% | -$48.8M | $18.10B |
| FY 2023 | $187.1M | $60.12B | — | — | -$34.6M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TMCI // BETA —
MRK // BETA 0.92